Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rat Monoclonal [clone GF1] (IgG2a,k) to Mouse CD209 / DC-SIGN
Rat Monoclonal [clone LWC06] (IgG2a) to Mouse CD209 / DC-SIGN
Western blot, Immunoprecipitation, Flow Cytometry
Mouse CD209 / DC-SIGN
Mouse (tested or 100% immunogen sequence identity)
IgG2a Monoclonal [LWC06]
Specificity and Use
CD209 / DC-SIGN antibody was raised against mouse CD209
This LWC06 antibody has been tested by immunoblotting and immunoprecipitation of CIRE in CIRE-transfected CHO cells. The reactivity of this antibody has been confirmed by immunoprecipitation of CIRE with LWC06 followed by immunoblotting with another CIRE-specific monoclonal antibody, 5H10 (LS-C106615) and, immunoprecipitation of CIRE with 5H10 followed by immunoblotting with LWC06.
PBS, pH 7.2, 150 mM sodium chloride, 0.09% sodium azide
CD209 Antibody, CD209 antigen Antibody, CD209 molecule Antibody, CDSIGN Antibody, CLEC4L Antibody, DC-SIGN Antibody, HIV gpl20-binding protein Antibody, DC-SIGN1 Antibody
Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response.